Weekly NADAC Price Changes
A weekly executive brief covering the pricing movements that matter most to market strategy and reimbursement planning.
Pricing pressure remained focused in a smaller set of anti-infective and endocrine products while broad supplier dispersion stayed relatively stable.
This release leaned more heavily on product-specific resets than on broad-based category repricing. Anti-infective moves stood out in percentage terms, but endocrine names still accounted for the largest weighted pressure across higher-volume products.
Key takeaways
- Anti-infective products produced the sharpest percentage moves this week.
- Weighted cost pressure remained anchored in endocrine therapies with larger dispensing exposure.
- Supplier dispersion did not broaden meaningfully across the rest of the market.
What to watch
Anti-infective durability
Whether this week’s anti-infective jumps represent a one-off reset or the start of a broader repricing cycle.
Endocrine exposure
Whether high-volume endocrine products continue to dominate weighted cost pressure.
Supplier spread
Whether more portfolios begin to show coordinated upward or downward movement.
Largest cost pressure
Largest absolute weekly price increase in the current release
Largest relief
Largest absolute weekly price decline in the current release
Top 10 NDCs by weekly price movement
Up to 10 changed products are shown. Each edition preserves its published price comparison.
| Drug | Manufacturer | NDC | Prev. price | Current price | Change |
|---|---|---|---|---|---|
| AZITHROMYCIN 250 MG TABLET | Teva | 00093015005 | $0.1862 | $0.2330 | +25.1% |
| AMOXICILLIN-CLAV 875-125 MG TAB | Aurobindo | 65862050399 | $0.2124 | $0.1839 | -13.4% |
| GLIPIZIDE ER 10 MG TABLET | Par | 49884074901 | $0.1077 | $0.1290 | +19.8% |
| LEVOFLOXACIN 500 MG TABLET | Sandoz | 07810040831 | $0.2794 | $0.2448 | -12.4% |
| INSULIN GLARGINE 100 U/ML PEN | Mylan | 49502069575 | $17.1100 | $20.0200 | +17.0% |
| NITROFURANTOIN MONO-MCR 100 MG | Lupin | 43386018301 | $0.3840 | $0.3358 | -12.6% |
| METFORMIN HCL ER 500 MG TABLET | Sun Pharma | 62756013888 | $0.0668 | $0.0774 | +15.9% |
| DOXYCYCLINE HYCLATE 100 MG CAP | Amneal | 65162038810 | $0.2610 | $0.2287 | -12.4% |
| SITAGLIPTIN 100 MG TABLET | Zydus | 68382028906 | $4.6120 | $5.1760 | +12.2% |
| CLINDAMYCIN HCL 300 MG CAPSULE | Teva | 00093084201 | $0.3014 | $0.2672 | -11.3% |
Drug market summaries
Manufacturer movement
Notes and methodology
How the weekly brief calculations were ranked, aggregated, and preserved for archive consistency.
Top mover ranking
The Top 10 table ranks NDCs by absolute weekly impact: the change in unit price multiplied by dispensing exposure when available.
Segment summaries
Drug markets, manufacturers, and therapeutic classes aggregate the same NDC-level deltas. Average move is the mean percent change, while impact is the summed dollar-weighted effect using absolute price impact because dispensing-volume weighting was unavailable.
Headline cards and archive stability
Most pressured class selects the largest positive class impact, and largest manufacturer swing selects the manufacturer with the largest aggregate absolute impact. Every weekly brief stores a frozen snapshot so archived pages do not drift when live NADAC data changes.
More archived editions
Each edition is permanently archived under its release date.
Week of August 19, 2026
Pricing pressure broadened across endocrine and respiratory products as a small set of high-volume therapies drove the week’s largest shifts.
The latest release shows a concentrated pattern of movement rather than a broad market-wide reset. Most of the week’s largest increases were concentrated in a narrow group of high-exposure products, while relief remained more fragmented across lower-cost oral therapies.
Week of August 12, 2026
Respiratory and cardiovascular names led a narrower repricing week as supplier-level changes remained concentrated rather than market-wide.
The prior release showed a more selective set of price resets, with supplier-specific moves driving most of the measured impact. Relief showed up in several established cardiovascular therapies, but broad deflation still did not develop across the full market.
Explore the broader trend ecosystem
Trends overview
Broader market movement and volatility across the full NADAC dataset.
Manufacturers
Compare suppliers and pricing dispersion across product portfolios.
Drug markets
Review generic alternatives by therapeutic market and current pricing.
Therapeutic classes
See category-level swings by prescribing class and market segment.
Understanding NADAC pricing
A primer on how NADAC works and why weekly movement matters.
Methodology
How the data is normalized and aggregated for public reporting.